Q32 Bio Inc.
QTTB Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$8.45
KIRA · Stoqly’s AI analyst, in plain words
- Q32 Bio Inc. had $53.7M of revenue in fiscal 2025. Over five years, revenue changed +81.9% a year on average.
- Its operating margin was 31.5%: of every 100 in sales, about 31 is left after running the business.
- Q32 Bio Inc. made $29.8M of net profit in fiscal 2025.
- Free cash flow was −$33.5M in fiscal 2025, −62.4% of revenue.
Market cap
$172M
P/E
2.7x
Revenue
$53.7M
Net income
$29.8M
Free cash flow
−$33.5M
Operating margin
31.5%
Q32 Bio Inc. in 30 seconds · fiscal 2025
Does it make a profit?
55.5%
Yes. It keeps 55.5% of every sale as profit.
Does profit turn into cash?
−62.4%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
2.7x
One share costs 2.7 times its yearly profit per share.
What Q32 Bio Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 10, 2026
- Legal name
- Q32 Bio Inc.
- CIK
- 0001661998
Q32 Bio Inc. · QTTB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $34.0M | $3.2M | −$6.7M | $0.0M | $53.7M |
| Revenue growth | 1,157.3% | −90.6% | −307.3% | — | — |
| Net interest income | — | — | $0.7M | $2.8M | $1.1M |
| Operating margin | −282.4% | −4,154.6% | 725.5% | — | 31.5% |
| Net income | −$95.8M | −$5.0M | −$53.7M | −$47.7M | $29.8M |
| Net margin | −281.9% | −156.0% | 808.0% | — | 55.5% |
| Diluted EPS | −$1.73 | −$0.09 | −$153.96 | −$6.58 | $2.42 |
| Cash | |||||
| Cash from operations | −$110M | −$114M | −$18.7M | −$67.7M | −$33.5M |
| Capital expenditure | $2.4M | $1.3M | $0.0M | $0.1M | $0.0M |
| Free cash flow | −$112M | −$115M | −$18.7M | −$67.8M | −$33.5M |
| FCF margin | −330.1% | −3,583.1% | 280.9% | — | −62.4% |
| Share count change | 20.4% | 3.8% | −99.4% | 2,666.5% | 27.5% |
| Debt and strength | |||||
| Cash and short-term investments | $156M | $175M | $25.6M | $78.0M | $48.3M |
| Shareholders' equity | $170M | −$131M | −$183M | $5.7M | $42.0M |
| Current ratio | 11.1x | 8.0x | 2.0x | 5.0x | 4.9x |
| Interest coverage | — | — | −32.2x | — | — |
| Returns and quality | |||||
| Return on equity | −52.4% | −25.7% | — | — | 125.1% |
| Return on tangible equity | −56.4% | — | — | −0.8% | 0.1% |
| Piotroski F-score | 3 | 1 | 2 | 3 | 3 |
| Altman Z'' | 0.1 | −8.2 | −19.4 | −8.4 | −2.1 |
Insiders bought, 12 months
$30.0M
2 insiders
Insiders sold, 12 months
$0.5M
3 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Q32 Bio Inc. · QTTB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $8.45 a share, the company is worth $172M: 2.7 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001661998). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.